Drug Profile
NXB 5886
Alternative Names: NXB-5886Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Nymox Pharmaceutical Corporation
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Streptococcal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Streptococcal-infections in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Streptococcal-infections in USA
- 08 Aug 2005 This compound is still in active development